 Jessica Rove
Concepts (236)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Transplantation | 7 | 2024 | 714 | 2.370 |
Why?
| | Cardiac Surgical Procedures | 5 | 2024 | 587 | 2.070 |
Why?
| | Tissue and Organ Procurement | 6 | 2024 | 319 | 1.480 |
Why?
| | Extracorporeal Membrane Oxygenation | 5 | 2023 | 347 | 1.110 |
Why?
| | Educational Personnel | 1 | 2022 | 11 | 0.760 |
Why?
| | Thoracic Surgery | 2 | 2024 | 141 | 0.760 |
Why?
| | Lidocaine | 1 | 2022 | 54 | 0.740 |
Why?
| | Gelatin | 1 | 2022 | 57 | 0.730 |
Why?
| | Surgeons | 2 | 2024 | 335 | 0.720 |
Why?
| | Heart Valve Prosthesis | 1 | 2023 | 121 | 0.710 |
Why?
| | Mitral Valve Insufficiency | 1 | 2022 | 73 | 0.700 |
Why?
| | Vascular Grafting | 1 | 2020 | 15 | 0.670 |
Why?
| | Phospholipases A2, Secretory | 4 | 2019 | 13 | 0.630 |
Why?
| | General Surgery | 1 | 2022 | 199 | 0.620 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2022 | 188 | 0.620 |
Why?
| | Echocardiography | 1 | 2022 | 647 | 0.610 |
Why?
| | Perfusion | 5 | 2024 | 226 | 0.590 |
Why?
| | Esophageal Neoplasms | 3 | 2017 | 338 | 0.530 |
Why?
| | Stomach Diseases | 1 | 2017 | 20 | 0.520 |
Why?
| | Organ Preservation | 4 | 2024 | 111 | 0.500 |
Why?
| | Anastomosis, Surgical | 1 | 2017 | 158 | 0.490 |
Why?
| | Esophagectomy | 1 | 2017 | 138 | 0.470 |
Why?
| | Deglutition Disorders | 1 | 2017 | 151 | 0.460 |
Why?
| | Enzyme Inhibitors | 4 | 2013 | 835 | 0.450 |
Why?
| | Coronary Artery Disease | 2 | 2020 | 716 | 0.450 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2023 | 863 | 0.440 |
Why?
| | Cognition | 1 | 2023 | 1226 | 0.440 |
Why?
| | Reoperation | 1 | 2017 | 599 | 0.420 |
Why?
| | Internship and Residency | 2 | 2020 | 1230 | 0.410 |
Why?
| | Group II Phospholipases A2 | 2 | 2012 | 10 | 0.390 |
Why?
| | Humans | 43 | 2024 | 141284 | 0.380 |
Why?
| | Cardiovascular Diseases | 2 | 2024 | 2091 | 0.360 |
Why?
| | Lung Neoplasms | 5 | 2019 | 2554 | 0.350 |
Why?
| | Quality of Life | 1 | 2023 | 3024 | 0.340 |
Why?
| | Retrospective Studies | 12 | 2024 | 16447 | 0.330 |
Why?
| | Bronchiectasis | 2 | 2012 | 111 | 0.320 |
Why?
| | Pneumonectomy | 2 | 2012 | 159 | 0.310 |
Why?
| | Heart | 2 | 2023 | 616 | 0.310 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 3 | 2012 | 1125 | 0.310 |
Why?
| | Postoperative Complications | 2 | 2017 | 2831 | 0.290 |
Why?
| | Tissue Donors | 4 | 2024 | 406 | 0.290 |
Why?
| | Apoptosis | 4 | 2013 | 2487 | 0.270 |
Why?
| | NF-kappa B | 5 | 2012 | 684 | 0.270 |
Why?
| | Mycobacterium Infections, Nontuberculous | 2 | 2012 | 363 | 0.250 |
Why?
| | Lung Transplantation | 2 | 2024 | 322 | 0.250 |
Why?
| | United States | 7 | 2024 | 15298 | 0.250 |
Why?
| | Brain Death | 2 | 2024 | 51 | 0.250 |
Why?
| | Osteogenesis | 2 | 2012 | 199 | 0.250 |
Why?
| | Thoracic Surgical Procedures | 2 | 2024 | 92 | 0.240 |
Why?
| | Adult | 13 | 2024 | 39319 | 0.230 |
Why?
| | Intercellular Adhesion Molecule-1 | 3 | 2019 | 142 | 0.230 |
Why?
| | Aortic Valve Stenosis | 2 | 2012 | 246 | 0.230 |
Why?
| | Aortic Valve | 2 | 2012 | 359 | 0.230 |
Why?
| | Consensus | 2 | 2024 | 538 | 0.220 |
Why?
| | Adenocarcinoma | 3 | 2013 | 897 | 0.220 |
Why?
| | Cell Proliferation | 3 | 2013 | 2502 | 0.220 |
Why?
| | Treatment Outcome | 7 | 2022 | 11216 | 0.210 |
Why?
| | RNA Interference | 2 | 2012 | 465 | 0.210 |
Why?
| | Organ Preservation Solutions | 1 | 2023 | 45 | 0.210 |
Why?
| | Tissue and Organ Harvesting | 1 | 2024 | 74 | 0.200 |
Why?
| | Primary Graft Dysfunction | 1 | 2023 | 34 | 0.200 |
Why?
| | Time Factors | 6 | 2024 | 6951 | 0.200 |
Why?
| | Physicians, Women | 1 | 2024 | 87 | 0.190 |
Why?
| | Biglycan | 1 | 2012 | 3 | 0.190 |
Why?
| | American Heart Association | 1 | 2024 | 299 | 0.190 |
Why?
| | Coronary Artery Bypass | 2 | 2024 | 251 | 0.190 |
Why?
| | Travel | 1 | 2023 | 139 | 0.190 |
Why?
| | Hernia, Inguinal | 1 | 2012 | 42 | 0.180 |
Why?
| | Herniorrhaphy | 1 | 2012 | 76 | 0.180 |
Why?
| | Jugular Veins | 1 | 2012 | 42 | 0.180 |
Why?
| | Technology Transfer | 1 | 2021 | 8 | 0.180 |
Why?
| | ras Proteins | 1 | 2012 | 145 | 0.180 |
Why?
| | Periodicals as Topic | 1 | 2024 | 198 | 0.180 |
Why?
| | Toll-Like Receptor 2 | 1 | 2012 | 120 | 0.180 |
Why?
| | Multicenter Studies as Topic | 1 | 2023 | 367 | 0.180 |
Why?
| | Gene Knockdown Techniques | 1 | 2012 | 331 | 0.180 |
Why?
| | Hypothermia, Induced | 1 | 2022 | 92 | 0.180 |
Why?
| | Echocardiography, Transesophageal | 1 | 2022 | 131 | 0.180 |
Why?
| | Spinal Cord Ischemia | 1 | 2022 | 60 | 0.180 |
Why?
| | Mitral Valve | 1 | 2022 | 98 | 0.180 |
Why?
| | Death | 1 | 2022 | 124 | 0.170 |
Why?
| | Pulmonary Valve Insufficiency | 1 | 2012 | 43 | 0.170 |
Why?
| | Thoracotomy | 2 | 2017 | 81 | 0.170 |
Why?
| | Computed Tomography Angiography | 1 | 2022 | 134 | 0.170 |
Why?
| | Graft Survival | 1 | 2023 | 502 | 0.170 |
Why?
| | Thoracic Surgery, Video-Assisted | 1 | 2011 | 45 | 0.170 |
Why?
| | Bronchi | 1 | 2012 | 261 | 0.170 |
Why?
| | Aortic Aneurysm, Thoracic | 1 | 2022 | 136 | 0.170 |
Why?
| | Calcinosis | 1 | 2012 | 238 | 0.160 |
Why?
| | Genetic Therapy | 1 | 2012 | 315 | 0.160 |
Why?
| | Coronary Circulation | 1 | 2020 | 134 | 0.160 |
Why?
| | Shock, Cardiogenic | 1 | 2020 | 59 | 0.160 |
Why?
| | Seizures | 1 | 2023 | 441 | 0.160 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2022 | 244 | 0.160 |
Why?
| | Phosphorylation | 5 | 2013 | 1753 | 0.160 |
Why?
| | Graft Rejection | 1 | 2023 | 545 | 0.160 |
Why?
| | Blotting, Western | 5 | 2013 | 1220 | 0.160 |
Why?
| | Blood Vessel Prosthesis Implantation | 1 | 2022 | 222 | 0.150 |
Why?
| | Transcatheter Aortic Valve Replacement | 1 | 2021 | 141 | 0.150 |
Why?
| | Blood Flow Velocity | 1 | 2020 | 411 | 0.150 |
Why?
| | Proto-Oncogene Proteins | 1 | 2012 | 621 | 0.150 |
Why?
| | Heart Arrest | 1 | 2022 | 397 | 0.140 |
Why?
| | Dinoprostone | 1 | 2019 | 179 | 0.140 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 2 | 2013 | 150 | 0.140 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 2 | 2013 | 182 | 0.140 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2024 | 1610 | 0.140 |
Why?
| | Mental Health | 1 | 2024 | 756 | 0.130 |
Why?
| | Phylogeny | 1 | 2022 | 997 | 0.130 |
Why?
| | Health Personnel | 1 | 2024 | 727 | 0.130 |
Why?
| | Respiratory Insufficiency | 1 | 2021 | 325 | 0.130 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2012 | 641 | 0.130 |
Why?
| | Gastric Emptying | 1 | 2017 | 36 | 0.130 |
Why?
| | Cell Movement | 1 | 2012 | 962 | 0.130 |
Why?
| | Antineoplastic Agents | 2 | 2012 | 2162 | 0.130 |
Why?
| | Critical Illness | 1 | 2023 | 852 | 0.130 |
Why?
| | Laparotomy | 1 | 2017 | 115 | 0.120 |
Why?
| | Delivery of Health Care | 1 | 2023 | 948 | 0.120 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2012 | 983 | 0.120 |
Why?
| | Cell Line, Tumor | 5 | 2012 | 3502 | 0.120 |
Why?
| | Hospital Mortality | 1 | 2020 | 938 | 0.120 |
Why?
| | Neoplasm Proteins | 1 | 2019 | 435 | 0.120 |
Why?
| | Anxiety | 1 | 2023 | 1078 | 0.120 |
Why?
| | Hydrogels | 1 | 2022 | 687 | 0.110 |
Why?
| | Aged | 8 | 2024 | 24836 | 0.110 |
Why?
| | Asphyxia | 1 | 2014 | 20 | 0.110 |
Why?
| | Heart Defects, Congenital | 1 | 2012 | 880 | 0.100 |
Why?
| | Registries | 1 | 2021 | 2205 | 0.100 |
Why?
| | Clinical Competence | 1 | 2020 | 1210 | 0.090 |
Why?
| | Veterans | 1 | 2024 | 1519 | 0.090 |
Why?
| | Middle Aged | 8 | 2024 | 34658 | 0.090 |
Why?
| | Thoracoscopy | 2 | 2012 | 58 | 0.090 |
Why?
| | Mutation | 1 | 2012 | 4006 | 0.090 |
Why?
| | Radiation Injuries | 1 | 2012 | 148 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2012 | 2047 | 0.080 |
Why?
| | Organ Transplantation | 2 | 2024 | 252 | 0.080 |
Why?
| | Male | 11 | 2024 | 70140 | 0.080 |
Why?
| | Transfection | 2 | 2012 | 932 | 0.080 |
Why?
| | RNA, Messenger | 3 | 2012 | 2815 | 0.080 |
Why?
| | Aorta, Thoracic | 2 | 2022 | 282 | 0.080 |
Why?
| | Mice | 2 | 2022 | 17969 | 0.070 |
Why?
| | Bone Morphogenetic Protein 2 | 2 | 2012 | 73 | 0.070 |
Why?
| | Female | 9 | 2024 | 75814 | 0.070 |
Why?
| | Alkaline Phosphatase | 2 | 2012 | 144 | 0.070 |
Why?
| | Patient Selection | 2 | 2012 | 685 | 0.070 |
Why?
| | Surveys and Questionnaires | 1 | 2020 | 5948 | 0.070 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2011 | 449 | 0.070 |
Why?
| | Animals | 3 | 2022 | 37328 | 0.060 |
Why?
| | Databases, Factual | 2 | 2020 | 1449 | 0.060 |
Why?
| | Aged, 80 and over | 3 | 2021 | 7948 | 0.060 |
Why?
| | Cell Survival | 2 | 2012 | 1123 | 0.050 |
Why?
| | Raffinose | 1 | 2023 | 29 | 0.050 |
Why?
| | Allopurinol | 1 | 2023 | 68 | 0.050 |
Why?
| | Donor Selection | 1 | 2024 | 77 | 0.050 |
Why?
| | Costs and Cost Analysis | 1 | 2024 | 219 | 0.050 |
Why?
| | Shock | 1 | 2024 | 105 | 0.050 |
Why?
| | Cell Growth Processes | 1 | 2012 | 52 | 0.050 |
Why?
| | Circulatory Arrest, Deep Hypothermia Induced | 1 | 2022 | 27 | 0.050 |
Why?
| | Ki-67 Antigen | 1 | 2012 | 111 | 0.050 |
Why?
| | Surgical Mesh | 1 | 2012 | 52 | 0.050 |
Why?
| | Lipoproteins, LDL | 1 | 2012 | 112 | 0.050 |
Why?
| | Paraplegia | 1 | 2022 | 61 | 0.050 |
Why?
| | Signal Transduction | 3 | 2013 | 5116 | 0.050 |
Why?
| | Workplace | 1 | 2024 | 265 | 0.050 |
Why?
| | Adenosine | 1 | 2023 | 251 | 0.050 |
Why?
| | Glutathione | 1 | 2023 | 361 | 0.050 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 173 | 0.040 |
Why?
| | Airway Management | 1 | 2012 | 79 | 0.040 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2012 | 269 | 0.040 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2012 | 272 | 0.040 |
Why?
| | Blood Vessel Prosthesis | 1 | 2022 | 139 | 0.040 |
Why?
| | Tumor Burden | 1 | 2012 | 314 | 0.040 |
Why?
| | Occupational Health | 1 | 2024 | 202 | 0.040 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2012 | 249 | 0.040 |
Why?
| | Secondary Prevention | 1 | 2012 | 241 | 0.040 |
Why?
| | Organ Size | 1 | 2012 | 476 | 0.040 |
Why?
| | Mice, Nude | 1 | 2012 | 700 | 0.040 |
Why?
| | Cells, Cultured | 2 | 2012 | 4149 | 0.040 |
Why?
| | Vascular Patency | 1 | 2020 | 109 | 0.040 |
Why?
| | Antitubercular Agents | 1 | 2012 | 203 | 0.040 |
Why?
| | Toll-Like Receptor 4 | 1 | 2012 | 275 | 0.040 |
Why?
| | Microscopy, Fluorescence | 1 | 2012 | 415 | 0.040 |
Why?
| | Cerebrovascular Circulation | 1 | 2022 | 271 | 0.040 |
Why?
| | Down-Regulation | 1 | 2012 | 636 | 0.040 |
Why?
| | Neoplasm Invasiveness | 1 | 2012 | 510 | 0.040 |
Why?
| | Syndrome | 1 | 2011 | 376 | 0.040 |
Why?
| | United States Department of Veterans Affairs | 1 | 2024 | 711 | 0.040 |
Why?
| | Molecular Targeted Therapy | 1 | 2012 | 420 | 0.040 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2012 | 917 | 0.040 |
Why?
| | Cattle | 1 | 2012 | 982 | 0.040 |
Why?
| | Antibodies, Neutralizing | 1 | 2012 | 321 | 0.040 |
Why?
| | Analysis of Variance | 1 | 2012 | 1312 | 0.040 |
Why?
| | A549 Cells | 1 | 2019 | 74 | 0.040 |
Why?
| | Postoperative Care | 1 | 2011 | 280 | 0.040 |
Why?
| | Anesthesia | 1 | 2012 | 248 | 0.040 |
Why?
| | Neoplasm Staging | 1 | 2012 | 1397 | 0.040 |
Why?
| | Glucose | 1 | 2023 | 1027 | 0.040 |
Why?
| | Pilot Projects | 1 | 2024 | 1820 | 0.040 |
Why?
| | Survivors | 1 | 2022 | 501 | 0.030 |
Why?
| | Stents | 1 | 2022 | 535 | 0.030 |
Why?
| | Risk | 1 | 2020 | 903 | 0.030 |
Why?
| | Burnout, Professional | 1 | 2024 | 458 | 0.030 |
Why?
| | STAT3 Transcription Factor | 1 | 2019 | 211 | 0.030 |
Why?
| | Biomarkers | 2 | 2012 | 4180 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2020 | 1505 | 0.030 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2012 | 1439 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2022 | 868 | 0.030 |
Why?
| | Comorbidity | 1 | 2020 | 1671 | 0.030 |
Why?
| | Lung Diseases | 1 | 2012 | 779 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2012 | 3577 | 0.030 |
Why?
| | Prognosis | 1 | 2012 | 4080 | 0.030 |
Why?
| | Age Factors | 1 | 2020 | 3295 | 0.020 |
Why?
| | Osteopontin | 1 | 2012 | 31 | 0.020 |
Why?
| | Core Binding Factor Alpha 1 Subunit | 1 | 2012 | 44 | 0.020 |
Why?
| | Insulin | 1 | 2023 | 2472 | 0.020 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2020 | 1039 | 0.020 |
Why?
| | Body Mass Index | 1 | 2020 | 2390 | 0.020 |
Why?
| | Heptanoic Acids | 1 | 2011 | 66 | 0.020 |
Why?
| | Pravastatin | 1 | 2011 | 45 | 0.020 |
Why?
| | Hypertension | 1 | 2020 | 1250 | 0.020 |
Why?
| | Radiotherapy | 1 | 2012 | 204 | 0.020 |
Why?
| | Simvastatin | 1 | 2011 | 62 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 2013 | 959 | 0.020 |
Why?
| | Cohort Studies | 1 | 2021 | 5809 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2013 | 438 | 0.020 |
Why?
| | Pyrroles | 1 | 2011 | 207 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2011 | 2765 | 0.020 |
Why?
| | Adolescent | 2 | 2023 | 22116 | 0.020 |
Why?
| | Up-Regulation | 1 | 2012 | 851 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2013 | 1220 | 0.020 |
Why?
| | Infant | 1 | 2012 | 9820 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2011 | 1182 | 0.020 |
Why?
| | Suicide | 1 | 2014 | 669 | 0.020 |
Why?
| | Child, Preschool | 1 | 2012 | 11511 | 0.020 |
Why?
| | Phenotype | 1 | 2012 | 3172 | 0.010 |
Why?
| | Child | 1 | 2012 | 22390 | 0.010 |
Why?
| | Young Adult | 1 | 2014 | 13727 | 0.010 |
Why?
|
|
Rove's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|